If you were diagnosed with a Roundup-linked cancer after the original 2020 settlement headlines, you may have heard that "Bayer already settled" or that "the Roundup cases are over." Neither is accurate. The cases are still being filed, still being tried, and still being resolved. What has changed is how. This piece explains the moving parts.
The 2020 Resolution and Why It Did Not End the Litigation
In June 2020, Bayer announced what it called a comprehensive resolution of Roundup litigation, with multiple billions of dollars allocated across three categories: existing cases, future cases, and a separate scientific advisory panel proposal that was ultimately rejected by Judge Vince Chhabria of the federal multidistrict litigation. The headline number was large. The reality on the ground was more complicated.
What the 2020 announcement did do: it resolved tens of thousands of pending cases through structured settlements with cooperating law firms. It also offered an early settlement track to many plaintiffs whose claims were already filed and whose diagnoses fit a defined matrix.
What it did not do: it did not resolve every plaintiff. It did not preclude new cases filed by people whose diagnoses came later. It did not stop trials — several have gone forward since 2020, with both plaintiff verdicts and defense verdicts. And it did not establish a binding future-claims program, because Judge Chhabria found problems with the structure Bayer originally proposed.
What Bayer's Strategy Looks Like in 2026
Bayer's approach to new Roundup cases in 2026 has settled into several recognizable patterns.
Selective trial defense
Bayer is not settling every case. It continues to try cases it believes it can win — particularly cases where exposure documentation is thin, the diagnosis is at the edge of the established science (a cancer subtype with weaker glyphosate linkage), or the plaintiff has competing risk factors the defense can use at trial. Plaintiffs' counsel know which cases will be defended and which will be candidates for resolution.
Structured settlement programs through specific firms
For cases that do fit the resolution profile, Bayer continues to negotiate with plaintiffs' firms in tranches. The specifics of any individual program are confidential, but the general structure involves a points-based matrix — weighing diagnosis type, exposure intensity, exposure duration, age, and other factors — that produces a per-case settlement value.
Verdict appeals and post-trial strategy
Bayer has aggressively appealed adverse verdicts. The most notable outcome of this strategy was the U.S. Supreme Court's June 2022 decision declining to hear Monsanto v. Hardeman, leaving in place the Ninth Circuit's affirmance of an adverse plaintiff verdict. The Court's denial of certiorari was a significant development for plaintiffs because it left the failure-to-warn theory intact under federal preemption analysis.
Continued attempts at preemption arguments
Bayer continues to argue, in various jurisdictions and various procedural postures, that federal law preempts state-law failure-to-warn claims because EPA has approved the existing Roundup label. The argument has succeeded in some forums and failed in others. The split has produced ongoing appellate activity and the prospect of further Supreme Court attention.
Lobbying for legislative protection at the state level
In several states, Bayer and its allies have pursued legislation that would limit certain failure-to-warn claims involving federally-registered pesticides. Some of these bills have advanced and some have not. The legislative landscape is one more reason new Roundup cases benefit from prompt filing rather than waiting to see how state law evolves.
What This Means for Cancer Survivors and Families Considering a Case
Several practical points follow from how Bayer is operating in 2026.
Settlement is possible, but it is not automatic
A diagnosis that fits the established Roundup-linked cancer profile — particularly Non-Hodgkin Lymphoma and its subtypes — can be resolved through a structured settlement track in many cases. Multiple Myeloma, Chronic Lymphocytic Leukemia (CLL), and B-cell Lymphoma cases are also being evaluated and resolved by Bayer in 2026 as the science around those subtypes has continued to develop.
The exposure documentation matters more than ever
Bayer is sharper than it was five years ago about which cases qualify for early resolution. The exposure documentation — what product, what years, what intensity, what use environment — carries substantial weight in matrix-based settlement evaluations. Cases with strong exposure documentation move differently from cases without it. Our companion guides on farmworker and agricultural worker cases and landscaper and groundskeeper exposure walk through what good documentation looks like in different work environments.
The Monsanto Papers are still central
Bayer inherited the document record, including the internal communications that have driven adverse verdicts and shaped settlement values. The plaintiff bar continues to use the documents in every case. Our deep-dive on the Monsanto Papers covers what they show and how they are used.
Filing now is materially different from filing later
Settlement matrices, jurisdictional consolidation status, and the substantive law itself all evolve. A case filed now enters under the current set of rules. A case filed later may enter under a different set. The general principle — that earlier filing generally creates more options — holds in 2026.
What the Case Still Has to Prove
Whether a case ultimately resolves through settlement or trial, the underlying proof framework is the same. Every Roundup case has to establish three things: the medical diagnosis (an oncologist confirms the cancer subtype and stages it), the exposure (a documented use history that connects the plaintiff to glyphosate-containing products), and the causal link between the two (expert testimony grounded in the IARC classification, the published epidemiology, and the company's own documents). Our companion piece on who qualifies for a Roundup lawsuit walks through what good cases look like across each of those elements.
What This Means for Conversations With Counsel
Two practical questions are worth asking any attorney evaluating your potential case:
- What is your direct experience with the current resolution environment? A firm that is actively handling Roundup cases in 2026 has visibility into how cases are being categorized, valued, and litigated right now. That visibility matters.
- How will the medical record be evaluated? At our firm, Herb Borroto, M.D., J.D., personally reads the pathology, the immunohistochemistry, the bone marrow biopsy (if applicable), and the oncology charts — before any outside expert is engaged and before any settlement value conversation begins. The medical workup drives everything else.
Bottom Line
Bayer's strategy in 2026 is not "settle every case" and not "fight every case." It is a managed program that resolves what fits a defined profile and litigates the rest. New cases continue to be filed. Verdicts continue to be returned. The Monsanto Papers continue to be the most powerful piece of evidence in the litigation. The conversation about whether your case fits the profile starts with the medical record and the exposure record, and it costs nothing to have.
If you or a family member used Roundup and were diagnosed with Non-Hodgkin Lymphoma, B-cell Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma, the free case review is exactly what it says. Herb Borroto reads the medical record himself. There is no obligation, and no fee unless we recover for you.